Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 352 results for covid-19

  1. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

  2. Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 [ID6261]

    In development [GID-TA11297] Expected publication date: 08 May 2024

  3. COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188)

    This guideline covers identifying, assessing and managing the long-term effects of COVID-19, often described as ‘long COVID’. It makes recommendations on care in all healthcare settings for adults, children and young people who have new or ongoing symptoms 4 weeks or more after the start of acute COVID-19. It also includes advice on organising services for long COVID.

  4. COVID-19 prescribing briefing: corticosteroids

    Dexamethasone and hydrocortisone are both corticosteroids; they have a role in treating COVID-19 in certain people.

  5. COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)

    The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection.

  6. COVID-19

    All NICE products on COVID-19. Includes any guidance and advice.

  7. Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)

    Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.

  8. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

  9. Sipavibart for preventing COVID-19 [ID6282]

    In development [GID-TA11352] Expected publication date: 26 February 2025

  10. Remdesivir for treating COVID-19 [ID3808]

    Awaiting development [GID-TA10721] Expected publication date: TBC

  11. Research to access pathway for investigational drugs for COVID-19 (RAPID C-19)

    A multi-agency collaboration to get treatments for COVID-19 to patients quickly

  12. Management of emergency department patients during the COVID-19 pandemic (Word)

    management during the COVID 19pandemicClinical guide for the management of emergency departmentpatients during the...

  13. Interim process and methods for developing rapid guidelines on COVID-19 (PMG35)

    This information sets out the process and methods used to develop rapid guidelines on COVID-19.

  14. Molnupiravir for treating COVID-19 [ID6340]

    In development [GID-TA11409] Expected publication date: 29 January 2025

  15. SYNE-COV for predicting COVID-19 outcomes (MIB264)

    NICE has developed a medtech innovation briefing (MIB) on SYNE-COV for predicting COVID-19 outcomes .